KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $38.1 million.

  • Sarepta Therapeutics' Other Non Operating Income rose 16657.09% to $38.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $74.2 million, marking a year-over-year increase of 77420.19%. This contributed to the annual value of $42.7 million for FY2024, which is 11102.24% up from last year.
  • Sarepta Therapeutics' Other Non Operating Income amounted to $38.1 million in Q2 2025, which was up 16657.09% from $10.1 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Other Non Operating Income ranged from a high of $38.1 million in Q2 2025 and a low of -$387.3 million during Q1 2023
  • Over the past 5 years, Sarepta Therapeutics' median Other Non Operating Income value was -$314000.0 (recorded in 2021), while the average stood at -$34.9 million.
  • In the last 5 years, Sarepta Therapeutics' Other Non Operating Income tumbled by 3984936.31% in 2022 and then soared by 19984.08% in 2023.
  • Sarepta Therapeutics' Other Non Operating Income (Quarter) stood at -$60.6 million in 2021, then plummeted by 107.06% to -$125.4 million in 2022, then soared by 90.17% to -$12.3 million in 2023, then surged by 181.59% to $10.1 million in 2024, then surged by 278.26% to $38.1 million in 2025.
  • Its last three reported values are $38.1 million in Q2 2025, $10.1 million for Q4 2024, and $11.8 million during Q3 2024.